AbbVie

News

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront.

News

AbbVie files Vraylar as add-on therapy for depression in US

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the dr

News

Aldeyra builds case for troubled dry eye drug reproxalap

Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h

News

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status.

News

Leo puts target on Dupixent in US as FDA clears tralokinumab

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab.

News

AbbVie prices first presbyopia drug Vuity at $80 per month

AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects.

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

AbbVie files Vraylar as add-on therapy for depression in US

Aldeyra builds case for troubled dry eye drug reproxalap

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

Leo puts target on Dupixent in US as FDA clears tralokinumab

AbbVie prices first presbyopia drug Vuity at $80 per month

Bayer gets swift review for Kerendia in type 1 diabetes

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks